Speaker: Eva M. Fallenberg, Munich/DE
Moderators: Federica Leone, Milan/IT; Monique Dorrius, Groningen/NL
Date: Wednesday, May 26, 2021
Time: 17:00-18:00 CEST

Speakers: Karin Dembrower, Stockholm/SE; Valeria Romeo, Naples/IT
Moderator: Doris Leithner, New York/US
Date: Tuesday, June 1, 2021
Time: 17:30-18:45 CEST

Speaker: Magda Marcon, Zurich/CH
Moderators: Marianna Fanizza, Pavia/IT; Ritse M. Mann, Nijmegen/NL
Date: Tuesday, July 6, 2021
Time: 17:30-18:30 CEST

Speaker: Marco Stampanoni, Villigen/CH
Moderators: Maria Adele Marino, Messina/IT; Pascal Baltzer, Vienna/AT
Date: Thursday, July 15, 2021
Time: 17:00-18:00 CEST

Speaker: Fabienne Thibault, Paris/FR
Moderator: Daly Avendano, Monterrey/MX; Katja Pinker, New York/US
Date: Thursday, April 15, 2021
Time: 17:00-18:00 CEST

What can you expect from this webinar?
Contrast-enhanced Mammography (CEM) is being increasingly used in routine practice. Using a panel of clinical cases, we will illustrate its main indications and its contribution to oncological diagnosis and therapeutic management. This includes diagnostic work-up of suspicious findings on mammography and/or US, determination of the initial tumour extent, evaluation of response to systemic treatment, aiding preoperative lesion localisation and diagnosing cancer recurrence. The clinical performance of CEM will be discussed in comparison with conventional mammography and ultrasound, and with breast MRI.

What will you learn during this webinar?
− The utility of CEM in daily practice both at the diagnostic stage and during the successive steps of breast cancer management
− Getting aware of advantages and limitations of CEM compared to breast MRI
− Getting to know some particular features of CEM images encountered during interpretation

Speaker: Marc Lobbes, Sittard-Geleen/NL
Moderators: Thiemo van Nijnatten, Maastricht/NL; Rubina Manuela Trimboli, Milan/IT
Date: Wednesday, March 24, 2021
Time: 17:00-18:00 CET

What you can expect from this webinar?
Contrast-enhanced mammography (CEM) is an upcoming breast imaging modality that relies on the injection of iodine based contrast agent and dual-energy mammography. The increased acceptance of CEM can be deducted from the increasing amount of installments and growing number of scientific publications. CEM indications might include: problem solving tool in equivocal findings during conventional mammography, preoperative staging, response monitoring in women treated with NAC, high risk screening, etc. However, it also starts with acquiring a robust CEM image. Hence, the current webinar will focus on the technical principles of CEM, patient handling and image acquisition. Some of the most common questions when initiating CEM within your breast center will be addressed, as well as the most common indications for CEM.

What can you learn during this webinar?
– Learn how to set up a CEM program in your hospital.
– Learn to acquire a high quality CEM image and know the technical principles behind it.
– Learn to cope with the most common artefacts and pitfalls.
– Discuss the most common indications for CEM.

Speaker: Daniela Bernardi, Milan/IT
Moderator: Lucia Grana, Lugo/ES
Date: Thursday, February 25, 2021
Time: 17:30-18:30 CET

Speaker: Sophia Zackrisson, Malmö/SE
Moderator: Heike Preibsch, Tübingen/DE
Date: Tuesday, Feburary 9, 2021
Time: 17:00-18:00 CET

What can you expect from this webinar?
This lecture will cover the basics and advances of digital breast tomosynthesis, DBT, and its role in breast cancer screening and clinical breast imaging. Scientific background data will be presented, and cases will be used to illustrate pearls and pitfalls with DBT in different situations.

What can you learn during this webinar?
– the technique behind digital breast tomosyntesis, strengths and limitations
– the current scientific evidence and recommendations for use of DBT in screening
– clinical situations where DBT might be useful

Speaker: Francesca Caumo, Verona/IT
Moderator: Elisabetta Giannotti, Nottingham/UK
Date: Wednesday, January 27, 2021
Time: 17:00-18:00 CET

What can you expect from this webinar?
Decide to undergo screening is an individual choice. The main questions are: how large the benefit of screening is in terms of reduced breast cancer mortality and how substantial the harm is in terms of interval cancers (defined as a cancer diagnosed after a negative mammographic screen and before the next routine screen), reduction of sensibility of mammography in dense breast and overdiagnosis, which is defined as the detection of cancers with screening which would not have become clinically apparent in the woman’s lifetime in the absence of screening.

There are two strategies to improve the effect of a screening program: find a better first level test- Automated Breast Ultrasound System (ABUS)-Magnetic Resonance Imaging (MRI)-Digital Breast Tomosynthesis (DBT)-Hand-Held Ultrasound (HHUS) or try the way to overcoming effect of density and make a better risk classification to have different screening strategies including other imaging modalities, in addition to mammography, that might improve early detection of breast cancer.
International strategy (Wisdom Study; Dense Study, MyPeBs) is thinking about tailored screening modifying interval screen and using other modality.

The objective of the webinar is to describe this experience and show our project: RiBS (RiskBasedScreening)